IGC · IGC Pharma Inc
United States · RS rating 25 · As of 2026-10-14
| Price | 0.25 USD |
|---|---|
| 1-day change | -6.7% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 31 / 50 / 19 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 4 / 12 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +83.2% |
| Distance from 52-week high | +40.0% |
| Market cap (USD) | $33.6M |